PGEN
PRECIGEN, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.66
+4.31%Year over year
Reported trailing growth
- Revenue
- +1875.0%
- EBITDA
- -16.8%
- EBIT
- +62.1%
- EPS
- —
- Free cash flow
- -66.0%
- Operating cash flow
- -72.3%
Forward estimates
Based on analyst estimates
- Revenue
- +303.1%
- EBITDA
- +289.2%
- EPS
- +160.8%
Three-year CAGR
- Revenue
- -28.9%
- EBITDA
- -97.2%
- EBIT
- +21.1%
- Net income
- -98.6%
- EPS
- —
- Free cash flow
- -17.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026